Aldeyra Therapeutics to Present at MOD Live! 2022 Meeting
MOD Live! 2022 is an interactive educational program that brings together optometrists and other eye care professionals to discuss new therapies and technologies as well as best practices for patient care. Aldeyra is among several companies selected to participate in the Therapeutics Pipeline session entitled, “The Future of Optometry – Pipeline Game Changers,” which focuses on therapies and technologies in development that may have the potential to change the way optometrists manage ocular diseases. The session will run from 4:30–5:45 pm CT on
Aldeyra develops innovative therapies designed to treat immune-mediated diseases. Our approach is to discover pharmaceuticals that modulate immunological systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Two of our lead product candidates, reproxalap and ADX-629, target pre-cytokine, systems-based mediators of inflammation known as RASP (reactive aldehyde species). Reproxalap is in Phase 3 clinical trials in patients with dry eye disease and allergic conjunctivitis. ADX-629, an orally administered RASP modulator, is in Phase 2 clinical testing for the treatment of systemic immune-mediated diseases. Our pipeline also includes ADX-2191 (intravitreal methotrexate 0.8%), in development for the prevention of proliferative vitreoretinopathy and the treatment of retinitis pigmentosa and primary vitreoretinal lymphoma. For more information, visit https://www.aldeyra.com/ and follow us on LinkedIn, Facebook, and Twitter.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220503006387/en/
Investor & Media Contact: